| Bioactivity | FAUC 213 is an orally active and highly selective dopamine D4 receptor complete antagonist with a Ki of 2.2 nM for hD4.4. FAUC 213 has less activity on D2 and D3 receptors (Kis of 3.4 μM, 5.3 μM for hD2, hD3, respectively). FAUC 213 can cross the blood-brain barrier (BBB). FAUC 213 exhibits atypical antipsychotic characteristic[1]. | ||||||||||||
| Invitro | FAUC 213 inhibits p5-HT1 (Ki=1.2 μM)，p5-HT2 (Ki=0.52 μM)，pα1 (Ki=0.27 μM)[1]. | ||||||||||||
| In Vivo | FAUC 213 (7.5-30 mg/kg; orally; single dose) significantly reduces this elevation in AMPH-induced locomotor hyper-activity only pre-treatment with 30 mg/kg. FAUC 213 significantly restores the prepulse inhibition (PPI) reduction caused by the apomorphine (APO) treatment with 30 mg/kg[1]. Animal Model: | ||||||||||||
| Name | FAUC 213 | ||||||||||||
| CAS | 337972-47-1 | ||||||||||||
| Formula | C18H19ClN4 | ||||||||||||
| Molar Mass | 326.82 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Frank Boeckler, et al. FAUC 213, a highly selective dopamine D4 receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia. Psychopharmacology (Berl). 2004 Aug;175(1):7-17. |